

12-10-01

A/BOYSE

PTO/SB/13/PCT (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

JC951  
11/09/01  
U.S. PTO20802  
10/01/09  
JC835 U.S. PTO  
11/09/01

## REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION		PRIOR APPLICATION EXAMINER	ART UNIT
PL	CLASS	SUBCLASS		
MWH-0002US2			Prema Mertz	1646

Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

This is a request for filing a  continuation  divisional application under 37 CFR 1.53(b), of pending prior international application Number PCT /US00/19094, filed on 13 JUL 00 entitled \_\_\_\_\_

Drug Target Isogenes: Polymorphisms in the Interleukin 4 Receptor Alpha Gene \_\_\_\_\_,

which designated the United States.

Note: 37 CFR 1.53(c) or (d) cannot be used to file a continuation or divisional application of an international application which has not entered the national stage.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	7 - 20 =	0	x \$ <u>18.00</u> =	\$ <u>0.00</u>
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	6 - 3 =	3	x \$ <u>84.00</u> =	<u>252.00</u>
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ _____ =	
				BASIC FEE (37 CFR 1.16(a))	<u>+ 740.00</u>
				Total of above Calculations =	<u>992.00</u>
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				<u>0.00</u>
				TOTAL =	<u>992.00</u>

1. Enclosed are the specification, claims and drawing(s).
2.  A statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
3.  The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 50-1293. A duplicate copy of this sheet is enclosed.
4.  A check in the amount of \$ \_\_\_\_\_ is enclosed.
5.  Amend the specification by inserting before the first line the sentence: "This application is a  continuation  division of international application number PCT \_\_\_\_\_, filed \_\_\_\_\_, (status, abandoned, pending, etc.)."

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## (REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION, PAGE 2)

6.  A declaration under 37 CFR 1.63 is enclosed.

7.  Priority of foreign application number \_\_\_\_\_, filed on \_\_\_\_\_ in \_\_\_\_\_  
is claimed under 35 U.S.C. 119(a) - (d).

The certified copy is enclosed.

8.  A preliminary amendment is enclosed.

9.  Also enclosed: See 1 in Addendum

Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record.)

Sandra L. Shaner  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511

9 - November - 2001

Date

Sandra L. Shaner

Signature

Sandra L. Shaner, Reg. No. 47,934

Typed or printed name

Inventor(s)

Assignee of complete interest. Certification under 37 CFR 3.73(b) is enclosed.

Attorney or agent of record

Filed under 37 CFR 1.34(a)

Registration number if acting under 37 CFR 1.34(a). \_\_\_\_\_.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew, Anne; Denton, R. Rex; Duda, Amy; Nandabalan, Krishnan; Stephens, Joel  
Claiborne; and Windemuth, Andreas K.

Application No.: To be determined  
Filed: November 9, 2001

Group No.: 1646  
Examiner: Prema Mertz

For: Drug Target Isogenes: Polymorphisms in the Interleukin 4 Receptor Alpha Gene

Assistant Commissioner for Patents  
Washington, D.C. 20231


## TRANSMITTAL

Enclosed herewith please find:

1. Request for filing a Division of an International Application
2. Division Application
3. Sequence Listing (69 pages)
4. Submission of Seq. Listing and statement pertaining thereto (2 pages)
5. Preliminary Amendment to claims (9 pages)
6. Transmittal of Information Disclosure Statement
7. Information Disclosure Statement Forms PTO/SB/O8A and PTO/SB/O8B
8. Cited references (9 total)
9. Combined declaration and power of attorney, fully executed (8 pages)
10. Return receipt postcard

Date: 9- November 2001

Reg. No. 47,934  
Tel. No. 203-786-3468




Sandra L. Shaner  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511

Page 1 of 1  
MWH-0002US2

## CERTIFICATION UNDER 37 C.F.R. section 1.10\*

(Express Mail label number is mandatory.)  
(Express Mail certification is optional.)

I hereby certify that this paper, along with any document referred to, is being deposited with the United States Postal Service on this date November 9, 2001, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL594594264US,  
304  
addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Cathy Wilcox  
(type or print name of person mailing paper)  
  
Signature of person mailing paper

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Chew, Anne; Denton, R. Rex; Duda, Amy; Nandabalan, Krishnan; Stephens, Joel Claiborne; and Windemuth, Andreas K.

Application No.: To be determined

Group No.: 1646

Filed: 9 November 2001

Examiner: Prema Mertz

For: Drug Target Isogenes: Polymorphisms in the Interleukin 4 Receptor Alpha Gene

**Box Sequence**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY  
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE  
AND/OR AMINO ACID SEQUENCE**

**IDENTIFICATION OF PERSON MAKING STATEMENT**

1. I, Sandra L. Shaner state the following:

**ITEMS BEING SUBMITTED**

2. Submitted herewith is/are:

"Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. section 1.821(c) and 37 C.F.R. sections 1.822 and 1.823.

A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. sections 1.821(e) and 1.824.

A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. section 1.821(f).

STATEMENT THAT "SEQUENCE LISTING"  
AND COMPUTER READABLE COPY ARE THE SAME  
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER


3. I hereby state:

Upon information and belief that the information recorded on the computer readable form of the Sequence Listing submitted herewith is identical to the paper Sequence Listing submitted herewith.

Respectfully submitted,

9-November - 2001

Date



Sandra L. Shaner  
Registration Number: 47,934  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511  
USA  
Tel. No. 203-786-3468

## Addendum

1. Sequence listing (print and computer readable forms), and statement pertaining thereto; Information Disclosure Statement Forms PTO/ SB/O8A AND PTO/SB/O8B AND 9 CITED REFERENCES